NYXH Nyxoah, S.A.: Earnings per share for the last 12 months

This market valuation chart for Nyxoah S.A. (NYXH) demonstrates the 19.60 metric, while the business relies on a steady demand for treatment despite logistics and sanctions risks. The development of an innovative implant for sleep apnea ensures patient comfort, enabling the company to maintain pricing power. The growth strategy is based on independently achieving medical milestones without mergers, focusing resources on the US market.
Financial and market metric breakdowns for Nyxoah S.A (NYXH)

Nyxoah S.A. is scaling the implementation of the Genio system for apnea therapy as it seeks expansion into the US market. This operational activity directly impacts net income dynamics, which this indicator measures via the rolling annual EPS growth. The metric captures the rate of earnings per share generation, allowing for an assessment of business efficiency from a fundamental perspective. By analyzing the YoY ttm net income per share changes on GURU.Markets, an investor can identify the risk of asset overvaluation when multiples are inflated.